Resonance Health Ltd
Company Profile
Business description
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group’s core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Contact
141 Burswood Road
Level 1
Burswood
PerthWA6100
AUST: +61 892865300
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
30 June 2026
Employees
18
Stocks News & Analysis
stocks
The ‘other’ AI chip behemoth that might just be getting started
stocks
Why ANZ changes aren’t just about cutting costs
stocks
Strong finish to the year for overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,095.20 | 28.80 | 0.32% |
| CAC 40 | 7,761.32 | 11.93 | 0.15% |
| DAX 40 | 23,626.87 | 91.58 | -0.39% |
| Dow JONES (US) | 45,524.57 | 186.77 | -0.41% |
| FTSE 100 | 9,225.39 | 17.14 | -0.19% |
| HKSE | 26,200.26 | 262.13 | 1.01% |
| NASDAQ | 21,964.49 | 85.01 | 0.39% |
| Nikkei 225 | 43,837.67 | 378.38 | 0.87% |
| NZX 50 Index | 13,276.24 | 22.51 | 0.17% |
| S&P 500 | 6,543.55 | 30.94 | 0.48% |
| S&P/ASX 200 | 8,830.40 | 40.00 | 0.46% |
| SSE Composite Index | 3,812.22 | 4.93 | 0.13% |